Alliance Global lowered the firm’s price target on Soligenix (SNGX) to $1.50 from $10 and keeps a Buy rating on the shares after the Data Monitoring Committee recommended halting the Phase 3 FLASH2 trial of HyBryte for the treatment of cutaneous T-cell lymphoma. The firm removed SGX301 from the stock’s valuation.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNGX:
- Soligenix announces interim results of Phase 3 trial of HyBryte in lymphoma
- Soligenix Halts FLASH2 Trial, Explores Strategic Alternatives
- Soligenix (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach
- Soligenix (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status
- Soligenix (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results